REGN vs SOLV · P/E 14, rev $14.34B vs P/E 9.1, rev $8.25B
Regeneron Pharmaceuticals Inc (REGN) versus Solventum Corp. (SOLV) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Solventum Corp. (SOLV) is a medical instruments & supplies company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SOLV revenue for 2024-12-31 was $8.25B. Net income was $479.0M. Revenue was up 0.7% from 2023-12-31 to 2024-12-31. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
Not investment advice. Open the REGN and SOLV stock pages for the full models.
Not investment advice.